Frankfurt
04.09.26 | 15:25
0,125 Euro
-2,34 % -0,003
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | LEE'S PHARM 1H26 Net Profit Up 41.4% to HKD95.01M; Interim DPS Hikes 59% to HKD0.035 | 1 | AASTOCKS | ||
| Mo | Lee's Pharmaceutical Holdings Ltd. Bottom Line Advances In H1 | 2 | RTTNews | ||
| Mo | LEE'S PHARM (00950): INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2026 | 1 | HKEx | ||
| LEES PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| Mo | LEE'S PHARM (00950): INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2026 | - | HKEx | ||
| 26.08. | LEE'S PHARM (00950): POSITIVE PROFIT ALERT | 1 | HKEx | ||
| 18.08. | LEE'S PHARM (00950): NOTICE OF BOARD MEETING | - | HKEx | ||
| 30.07. | LEE'S PHARM (00950): VOLUNTARY ANNOUNCEMENT - INVESTIGATIONAL NEW DRUG APPLICATION IN CHINA FOR PROPRIETARY ADC PROJECT ZK2401 ACCEPTED BY NMPA | 3 | HKEx | ||
| 21.07. | Ashlins schließt Lizenzabkommen mit Lee's Pharm für Interferon-Wirkstoff | 2 | Investing.com Deutsch | ||
| 17.07. | LEE'S PHARM (00950): VOLUNTARY ANNOUNCEMENT - ENTERING INTO EXCLUSIVE LICENSE-OUT AND SUPPLY AGREEMENT WITH ASHLINS FOR INTERFERON ALPHA-2B PRODUCTS ... | 1 | HKEx | ||
| 16.06. | LEE'S PHARM (00950): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE PROGRAM UNDER THE REPURCHASE MANDATE | 1 | HKEx | ||
| 01.06. | LEE'S PHARM (00950): VOLUNTARY ANNOUNCEMENT - FUNDING APPROVED FOR SYNTHETIC SURFACTANT PROJECT | 1 | HKEx | ||
| 27.05. | Dividendenbekanntmachungen (27.05.2026) | 8.803 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAC TECHNOLOGIES HOLDINGS INC ADR US0003041052 0,0446 USD 0,0384 EUR ADVANCE TERRAFUND REIT BG1100025052 - 0,065 EUR APOTEA AB SE0023313762 0... ► Artikel lesen | |
| 21.05. | LEE'S PHARM (00950): ANNUAL GENERAL MEETING HELD ON 21 MAY 2026 - POLL RESULTS | 1 | HKEx | ||
| 11.05. | LEE'S PHARM (00950): CONNECTED TRANSACTION - INVESTMENT IN PARTNERSHIP FUND | 1 | HKEx | ||
| 24.04. | LEE'S PHARM (00950): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 24.04. | LEE'S PHARM (00950): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 23.04. | LEE'S PHARM (00950): PROXY FORM | - | HKEx | ||
| 23.04. | LEE'S PHARM (00950): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | LEE'S PHARM (00950): GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES, RE-ELECTION OF DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | LEE'S PHARM (00950): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 1 | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 129,66 | -0,25 % | Can Bixlenvo Unlock New Growth for Gilead's HIV Business? | ||
| ZOETIS | 65,32 | +0,09 % | Zoetis: Zwei Kurszielsenkungen - das steckt dahinter | ||
| SINOPHARM | 1,734 | +1,02 % | SINOPHARM (01099): FORM OF PROXY FOR EXTRAORDINARY GENERAL MEETING TO BE HELD ON TUESDAY, 15 SEPTEMBER 2026 | ||
| CSPC PHARMA | 1,030 | -0,79 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - PHASE I CLINICAL TRIAL OF SYH2056 TABLETS FOR THE TREATMENT OF DEPRESSION OFFICIALLY INITIATED IN CHINA | ||
| WUXI BIOLOGICS | 5,370 | -0,92 % | WUXI BIO (02269): NEXT DAY DISCLOSURE RETURN | ||
| SHANGHAI FOSUN PHARMACEUTICAL | 1,800 | +1,52 % | Gland Pharma block deal: 82.5 lakh shares likely to change hands; Fosun Pharma among sellers | ||
| GEDEON RICHTER | 35,120 | 0,00 % | Gedeon Richter Plc.: Notification on change in voting rights | ||
| DR REDDYS | 10,200 | 0,00 % | Dividendenbekanntmachungen (24.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADRIANO CARE SOCIMI SA ES0105405007 - 0,1215 EUR ALEXANDERWERK AG DE000A37FTW0 - 0,5 EUR ARROWMARK FINANCIAL CORP US8617801043 0... ► Artikel lesen | |
| MEDIPHARM LABS | 0,046 | -5,15 % | MediPharm Labs Corp.: MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA | Q2 2026 Adjusted EBITDA1 of $0.9M, the Company's strongest quarterly performance since 20192Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025OPEX decreased 44% in Q2 2026... ► Artikel lesen | |
| ASPEN PHARMACARE | 8,200 | +1,23 % | Earnings Call: Aspen Pharmacare hebt Gewinnprognose für GJ 2026 an und stellt starkes Wachstum für 2027 in Aussicht | ||
| SHANGHAI PHARMACEUTICALS | 1,290 | +2,38 % | SH PHARMA (02607): INTERIM DIVIDEND FOR THE SIX MONTHS ENDED 30 JUNE 2026 (UPDATED) | ||
| LUYE PHARMA | 0,206 | +1,98 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT MRNA VACCINE LY01620 FOR THE TREATMENT OF CERVICAL PRECANCEROUS LESIONS AND HPV-RELATED TUMORS TO ENTER INTO ... | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,086 | +2,38 % | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT - XUANZHU BIOPHARM AND INNOBIC REACHED A COMMERCIAL COOPERATION FOR BIREOCICLIB IN THE THAILAND MARKET | ||
| HANSOH PHARMACEUTICAL | 3,812 | -4,41 % | HANSOH PHARMA HS-20093 for Injection NDA for Treating Small Cell Lung Cancer Accepted by China's NMPA | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,474 | 0,00 % | CHINARES PHARMA Unit China Resources Double-Crane's Lomustine Capsules Obtain Drug Registration Certificate |
LEES PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,003 (-2,34 %) liegt der Kurs bei 0,125 Euro. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LEES PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.